Reference strains used in this study.
Abstract
Leishmaniasis is caused by Leishmania sp., which is transmitted to human beings and reservoirs by phlebotomine sand flies, with worldwide prevalence of approximately 12 million cases with population at risk of approximately 350 million. Cutaneous leishmaniasis (CL) is the most widespread form, causing localized skin lesions (LCL), mucocutaneous leishmaniasis (MCL), or nodular lesions in diffused cutaneous leishmaniasis (DCL). American CL includes LCL and DCL caused by Leishmania mexicana complex and MCL caused by the Leishmania braziliensis complex. In Mexico, CL is distributed in three endemic areas, Gulf of Mexico, Pacific of Mexico, and Central Mexico. In order to monitor clinical outcome and adequately target treatment as well as epidemiologic studies, diagnostic kinetoplast DNA (kDNA), polymerase chain reaction (PCR), Southern and dot blotting, and ITS1 PCR-RFLP of Leishmania DNA were evaluated in samples and Leishmania isolates from patients with cutaneous ulcers from several endemic areas. In Mexico, LCL can be caused by the L. mexicana, L. braziliensis, or both complexes. DCL is caused by L. (L.) mexicana or Leishmania (L.) amazonensis and visceral leishmaniasis (VL) by Leishmania (L.) chagasi and L. (L.) mexicana in immunocompromised patients. The geographic range in which CL is endemic has increased due to urbanization, new settlements, and ecological, social, and educative conditions, which favors its permanence and transmission.
Keywords
- Leishmania
- cutaneous leishmaniasis
- Mexico
- epidemiology
- ecology
1. Introduction
Leishmaniasis is a group of clinical entities present in 79 countries at a rate of 400,000 cases per year. The World Health Organization estimates a worldwide prevalence of approximately 12 million cases with population at risk of approximately 350 million. It is caused by a parasitic protozoan, which belongs to the
Cutaneous leishmaniasis (CL) is the most widespread form, causing primary localized skin lesions from which parasites can disseminate to the nasopharyngeal mucosa and cause mucocutaneous leishmaniasis (MCL) or disseminate to the entire body as nodular lesions in diffused cutaneous leishmaniasis (DCL). Visceral leishmaniasis (VL) is the most severe form of the disease; according to the WHO in areas endemic for VL, many people have asymptomatic infection and a concomitant HIV infection increases the risk of developing active VL by between 100 and 2320 times [1].
VL is characterized by irregular fever, weight loss, swelling of the liver and spleen, and anemia. After recovery, patients sometime develop chronic DCL [2, 3].
American cutaneous leishmaniasis is characterized by a spectrum of clinical presentations caused by
In Mexico, Seidelin first recorded LCL caused by
2. Materials and methods
In order to find a diagnostic method for leishmaniasis that combines high sensitivity with species differentiation in the field, rapid diagnosis, and low cost, several molecular targets for a diagnostic PCR were evaluated from patients with cutaneous ulcers suspected of having LC from several endemic areas. The target was minicircle kinetoplast DNA (kDNA) using specific primers or probes with the PCR and Southern or dot blotting [11] and PCR-RFLP of the internal transcribed spacer 1 (ITS1) [10, 12].
Distribution of CL or VL in social, educative, and ecological conditions was recorded. The patients diagnosed with CL were treated with meglumine antimoniate (Glucantime®).
2.1. Patient population
In these studies, we evaluated samples from patients with clinical symptoms and skin lesions suggestive of CL, MCL, and DCL from several endemic areas of Mexico—Campeche, Tabasco, Veracruz, Nayarit and Chiapas, and Quintana Roo—or samples from VL patients from Chiapas and Tabasco states. The clinical samples were taken on filter papers or smears, needle aspirates, and tissue biopsy samples (1–2 mm) from the edge of cutaneous or bone marrow aspirates (Figure 1).

Figure 1.
Map of Mexico, showing the Ocean Pacific, Gulf of Mexico, and Central Leishmaniasis endemic regions.
2.2. Ethical considerations
For bleeding human beings for diagnosis and therapeutics, informed consent was obtained from all the adults who participated in the study. Consent for including young children was obtained from their parents or guardians. The ethics committee of the corresponding health authorities, in agreement with International Ethical Guidelines for Biomedical Research involving human subjects (Norma Oficial Mexicana de Salud: NOM-003-SSA 2-1993), reviewed and approved the protocols of the present studies.
2.3. Leishmania reference strains and Mexican isolate culture conditions
Reference
Number | Strain | Code | |
---|---|---|---|
1 | MHOM/BZ/82/BEL21 | BEL21 | |
2 | MHOM/BZ/62/M379 | M379 | |
3 | IFLA/BR/67/PH8 | PH8 | |
4 | MHOM/BR/73/M2269 | M2269 | |
5 | MHOM/PE/84/LC53 | LC53 | |
6 | MHOM/BR/84/LTB300 | LTB300 | |
7 | MHOM/BR/75/M2903 | M2903 | |
8 | MHOM/BR/75/M2904 | M2904 | |
9 | MHOM/BR/75/M4147 | M4147 | |
10 | MHOM/PE/84/LC26 | LC26 | |
11 | MHOM/CR/87/NEL3 | NEL3 | |
12 | MHOM/PA/72/LS94 | LS94 | |
13 | MHOM/IN/80/DD8 | DD8 | |
14 | MHOM/BR/74/PP75 | PP75 |
Table 1.
Number | Code | Origin | Clinical expression | |
---|---|---|---|---|
1 | MHOM/MX/88/HRC JS | Tabasco | DCL | |
2 | MHOM/MX/88/HRC MC | Tabasco | LCL | |
3 | MHOM/MX/84/ISET GS | Tabasco | DCL | |
4 | MHOM:MX:83:UAVY CV | Yucatan | LCL | |
5 | MHOM/MX/85/ISET HF | Veracruz | DCL | |
6 | LVER | Veracruz | DCL | |
7 | REP | Campeche | LCL | |
8 | MHM/MX/06/ENCB/MIC | Campeche | LCL | |
9 | MHM/MX/06/ENCB CDL | Campeche | LCL | |
10 | MHM/MX/06/ENCB FDL | Campeche | LCL | |
11 | CR | Campeche | LCL | |
12 | PVS | Campeche | LCL | |
13 | RGL | Campeche | LCL | |
14 | FJJ | Campeche | LCL | |
15 | ESP | Campeche | LCL |
Table 2.
Mexican isolates of
2.4. Isolation of DNA
Clinical specimens cut from the filter paper or eluted from the smear, bone marrow aspirates, skin aspirates, and tissue biopsy samples (1–2 mm) were incubated in 250 μL of cell lysis buffer for 1 h at 56°C. DNA from
2.5. Polymerase chain reaction
PCR analysis of kDNA for subgenus
2.6. PCR analysis of genomic DNA of L. (V. ) braziliensis
PCR species specific for nuclear DNA from variants of
2.7. PCR analysis of the internal transcribed spacer 1 (ITS1)
Some samples were analyzed for ITS1 PCR using the primers: LITSR and L5.8S [10]. Amplification conditions were as described [12]. PCR products were digested with
2.8. Southern or dot blot hybridization of kDNA PCR products of biopsies, isolates and Leishmania reference strains
The kDNA PCR products of clinical samples, Mexican isolates and reference strains, were Southern or dot blotted onto nylon membranes and were hybridized with the cloned fragments of kDNA used as probes: B4Rsa, which hybridizes specifically to members of the
2.9. Administration of meglumine antimoniate (Glucantime®)
Patients diagnosed with CL accepted treatment with meglumine antimoniate (Glucantime®). Glucantime is marketed in 5 mL ampules containing 1.5 g of N-methyl-glucamine antimoniate, which corresponds to 425 mg of Sb51. Treatment consisted in one ampule by intramuscular injection per day until healing [19].
3. Results
Primers DeB8 and AJS1, specific for the
PCR with the primers M1 and M2 specific for the
PCR specific for the
In order to have a more accurate identification of the
PCR with specific primers D1 and D2 for the
PCR products of the kDNA of Mexican strains of
PCR products amplified with primers B1 and B2, specific for the
PCR with specific primers for ITS1 resulted in the amplification of the
Most of the Mexican strains and isolates of
In relation to the clinical samples from Campeche, most of them amplified a restriction pattern similar to the
4. Discussion
In Mexico since 1985, cases of LCL, DCL, MCL, and VL clinical expressions were reported in 15 states; the species involved were
In Nayarit, state of the Pacific endemic region, LCL was recorded in Caleras de Cofrados since 1987 [22], a district near Tepic, the state capital city (Figure 1). The etiological agent was thought to be
Biopsies, clinical samples, and isolates from LCL patients from several districts of Campeche state, mainly from Calakmul, were PCR amplified with specific primers for kDNA of
In central Calakmul 15% of the cases were infected with
In southern Calakmul 25% of the cases were infected with

Figure 2.
Patients from the endemic Gulf of Mexico region, with skin lesions suffering from cutaneous leishmaniasis.

Figure 3.
Communities situated in the leishmaniasis endemic region of Gulf of Mexico. People in these villages farm chili crops around their houses, located very near the forest close to the border of Belize and Guatemala.
Regarding to the animal reservoirs,
We found most of the cases of DCL in the states of Tabasco and Veracruz (Figure 1). These states have a common border in the endemic region of the Gulf of Mexico and are characteristically tropical rain forest, with considerable rainfall and important agricultural activities, including the production of cocoa, sugar cane, and rubber. We collected isolates from patients with DCL or LCL in these states and some from Campeche. Their DNA was amplified with primers M1 and M2 [17] specific for kDNA of
In Mexico, it has been reported that VL was caused by
Treatment of CL patients with
In the endemic areas evaluated in the present studies, the risk factors associated with CL were identified as the human colonization of large areas of previously untouched rain forests, where CL is endemic. The urbanization and deforestation are important factors because the
5. Conclusion
In conclusion, our findings are interesting because we have shown that in the typical endemic regions of Gulf of Mexico and Ocean Pacific of Mexico, CL can be caused by several species of the
Acknowledgments
Financial support for this research was provided by Secretaría de Investigacion y Posgrado, Instituto Politecnico Nacional, Mexico, and Conacyt. Amalia Monroy-Ostria is a fellow of COFAA, Instituto Politecnico Nacional, Mexico. We thank Erik Fabila-Monroy, MBA, for reviewing the English of the manuscript.
References
- 1.
World Health Organization. www.who.int/leishmaniasis/en [Internet]. [Accessed: 8 July, 2016]. Fact sheet No. 375; 2014. - 2.
Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis. 2007; 7 :581–596. - 3.
Desyeux P. Leishmania and Leishmaniasis: worldwide increasing risk factor for leishmaniasis. Med Microbiol Immun. 2001;190 :77–79. - 4.
Lainson R. The American leishmaniasis: some observations on their ecology and epidemiology. Trans R Soc Trop Med Hyg. 1983; 77 :569–596. - 5.
Seidelin H. Leishmaniasis and babesiasis in Yucatan. Ann Trop Med Parasit. 1912; 6 :295–299. - 6.
Velasco-Castrejon O, Savarino S, Neva F, Guzman-Bracho C. Los agentes etiologicos de las leishmaniasis cutaneas en Mexico. Presencia de L. braziliensis en Mexico. Rev Lat Amer Microbiol. 1989;31 :231–234. - 7.
CENAPRECE, Secretaria de Salud, Mexico. Programa de Acccion Especifico: Prevencion y Control de las Leishmaniasis. In: Secretaria de Salud, publisher Programa de Acccion Sectorial; 2013–2018. Mexico City, Mexico. - 8.
De Brujin MHL, Barker DC. Diagnosis of New World Leishmaniasis: specific detection of species of the Leishmania braziliensis complex by amplification of kinetoplast DNA. Acta Trop. 1992;52 :45–58. - 9.
Fernandes O, Murthy VK, Kurath U, Degrave WM, Campbell DA. Mini-exon gene variation in human pathogenic Leishmania species. Mol Biochem Parasit. 1994;66 :261–271. - 10.
El Tai NO, Osman OF, El Fari M, Presber W, Schönian G. Genetic heterogeneity of ribosomal international transcribed spacer (its) in clinical samples of Leishmania donovani spotted on filter paper as revealed by single-strand conformation polymorphisms (sscp) and sequencing. Trans R Soc Trop Med Hyg. 2000;94 :1–5. - 11.
Monroy-Ostria A, Sanchez-Tejeda G. Molecular probes and the polymerase chain reaction for detection and typing of Leishmania species in Mexico. Trans R Soc Trop Med Hyg. 2000;96 :Supplement 1 S1/101–S1/104. - 12.
Monroy-Ostria A, Nasereddin A, Monteon VM, Guzman-Bracho C, Jaffe CL. ITS1 PCR-RFLP diagnosis and characterization of Leishmania in clinical samples and strains from cases of human cutaneous leishmaniasis in states of the Mexican Southeast. Interdiscip Perspect Infect Dis. 2014;2014 :6 pages. DOI: 10.1155/2014/607287 - 13.
Smith AJ, Ghosh A, Hassan MQ, Basu D, De Brujin MHL, Adhya S. Rapid and sensitive detection of Leishmania kinetoplast DNA from spleen and blood samples of kala-azar patients. Parasitology. 1992;105 :183–192. - 14.
Eresh S, McCallum SM, Barker DC. Identification and diagnosis of Leishmania mexicana complex isolates by polymerase chain reaction. Parasitology. 1994;109 :423–433. - 15.
Hernandez-Montes O. Diseño de herramientas moleculares para el estudio de la heterogeneidad genetica de aislados de Leishmania mexicana [thesis]. Mexico: National School of Biological Sciences, National Polytechnic Institute; 2000. 184 p. - 16.
Piarroux R, Azaies R, Lossi AM, Reynier P, Muscatelli F, Gambarelli F, Fontes M, Dumon H, Quilici M. Isolation and characterization of a repetitive DNA sequence from Leishmania infantum : development of a visceral leishmaniasis polymerase chain reaction. Am J Trop Med Hyg. 1993;48 :364–369. - 17.
Hernandez MO, Monroy OA, McCann S, Barker DC. Identification of Mexican Leishmania species by analysis of PCR amplified DNA. Acta Trop. 1998;71 :139–153. - 18.
Rodriguez N, De Lima H, Rodriguez A, Brewster S, Barker DC. Genomic DNA repeat from Leishmania (Viannia )braziliensis (Venezuelan strain) containing simple repeats and microsatellites. Parasitology. 1997;115 :349–358. - 19.
Hernandez Rivera PM, Hernandez-Montes O, Chiñaz-Perez A, Batiza-Avelar JM, Sanchez-Tejeda G, Wong-Ramírez C, Monroy-Ostria A. Study of cutaneous leishmaniasis in the State of Campeche (Yucatan Peninsula), Mexico over a period of two years. Salud Publica Mex. 2015; 57 :58–65. - 20.
Sanchez-Tejeda G, Rodriguez N, Parra CI, Hernandez MO, Barker DC, Monroy OA. Cutaneous leishmaniasis caused by members of Leishmania braziliensis Complex, in Nayarit, State of Mexico. Mem I Oswaldo Cruz. 2001;96 :15–19. - 21.
Monroy-Ostria A, Hernandez-Montes O, Barker DC. Aetiology of visceral leishmaniasis in Mexico. Acta Top. 2000; 75 :155–161. - 22.
Velasco CO. Las leishmaniasis en Mexico. Rev Lat Amer Micobiol. 1987; 29 :119–126. - 23.
Pech-May A, Escobedo-Ortegon FJ, Berzunza-Cruz M, Rebollar-Tellez EA. Incrimination of four sandfly species previously unrecognized as vectors of Leishmania parasites in Mexico. Med Vet Entomol. 2010;24 :150–161. - 24.
Canto-Lara SB, Van Wynsberghe NR, Vargas-Gonzalez A, Ojeda-Farfan FF, Andrade-Narvaez FJ. Use of monoclonal antibodies for the identification of Leishmania spp. Isolated from humans and wild rodents in the State of Campeche, Mexico. Mem I Oswaldo Cruz. 1999;94 :305–309. - 25.
Velasco CO, Savarino SJ, Walton BC, Gam A, Neva F. Diffuse cutaneous leishmaniasis in Mexico. Am J Trop Med Hyg. 1989; 4 :280–288. - 26.
Ramos-Santos C, Hernandez-Montes O, Sanchez-Tejeda G, Monroy-Ostria A. Visceral leishmaniosis caused by Leishmania (L. )mexicana in a Mexican patient with human immunodeficiency virus infection. Mem I Oswaldo Cruz. 2000;95 :729–733. - 27.
Hernandez E, Rodriguez N, Wessolossky M, Convit J. Visceral Leishmaniasis due to a Leishmania variant that shares kinetoplast DNA sequences withLeishmania braziliensis andLeishmania mexicana in a patient infected with human immunodeficiency virus: identification of theLeishmania species with use of the polymerase chain reaction. Clin Infect Dis. 1995;21 :701–702.